Proteomic analysis for the identification of serum diagnostic markers for joint hypermobility syndrome

Watanabe,Atsushi; Satoh,Kazumi; Maniwa,Tomoko; Matsumoto,Ken-Ichi

doi:10.3892/ijmm.2015.2437

Proteomic analysis for the identification of serum diagnostic markers for joint hypermobility syndrome

Authors:
- Atsushi Watanabe
- Kazumi Satoh
- Tomoko Maniwa
- Ken-Ichi Matsumoto
View Affiliations

Affiliations: Division of Clinical Genetics, Nippon Medical School Hospital, Tokyo 113-8603, Japan, Department of Biosignaling and Radioisotope Experiment, Interdisciplinary Center for Science Research, Organization for Research, Shimane University, Izumo, Shimane 693-8501, Japan
Published online on: December 18, 2015 https://doi.org/10.3892/ijmm.2015.2437
Pages: 461-467

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Joint hypermobility syndrome (JHS) (also termed Ehlers-Danlos syndrome, hypermobility type) is a heritable connective tissue disorder which is characterized by generalized joint hypermobility, chronic pain, dizziness, fatigue, and minor skin changes. However, it has yet to be determined in patients with JHS whether specific genetic factors are involved in the risk of developing the disorder. Therefore, interventions have been limited to symptomatic treatments, and biomarkers for diagnosis and therapy have not yet been identified. In the present study, to identify potential serum biomarkers for JHS, we examined proteins with differential levels in sera from patients with JHS and in sera from control individuals using isobaric tags for relative and absolute quantitation (iTRAQ) labeling in combination with nano LC-MALDI-TOF/TOF-MS/MS followed by ProteinPilot analysis. In the sera of patients with JHS, a total of 106 proteins with differential levels were identified, and they were further narrowed down to 6 proteins (p<0.05, patient vs. control). Of the 6 proteins, proteins involved in the complement system including complement C1r subcomponent (C1R), vitronectin (VTN), complement component C9 (C9), and C4b-binding protein alpha chain (C4BPA) were identified as increased proteins in sera from patients with JHS compared with those in sera from controls. We confirmed increased levels of C1R and VTN in sera from patients with JHS by western blot analyses. The results indicate the possibility of a locally occurring inflammatory process in patients with JHS.

View Figures

View References

1	Grahame R: Joint hypermobility and genetic collagen disorders: are they related? Arch Dis Child. 80:188–191. 1999. View Article : Google Scholar : PubMed/NCBI
2	Malfait F, Hakim AJ, De Paepe A and Grahame R: The genetic basis of the joint hypermobility syndromes. Rheumatology (Oxford). 45:502–507. 2006. View Article : Google Scholar
3	Castori M, Morlino S, Celletti C, Ghibellini G, Bruschini M, Grammatico P, Blundo C and Camerota F: Re-writing the natural history of pain and related symptoms in the joint hypermobility syndrome/Ehlers-Danlos syndrome, hypermobility type. Am J Med Genet A. 161A:2989–3004. 2013. View Article : Google Scholar : PubMed/NCBI
4	Tinkle BT, Bird HA, Grahame R, Lavallee M, Levy HP and Sillence D: The lack of clinical distinction between the hypermobility type of Ehlers-Danlos syndrome and the joint hypermobility syndrome (a.k.a. hypermobility syndrome). Am J Med Genet A. 149A:2368–2370. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zweers MC, Bristow J, Steijlen PM, Dean WB, Hamel BC, Otero M, Kucharekova M, Boezeman JB and Schalkwijk J: Haploinsufficiency of TNXB is associated with hypermobility type of Ehlers-Danlos syndrome. Am J Hum Genet. 73:214–217. 2003. View Article : Google Scholar : PubMed/NCBI
6	Beighton P: Hypermobility scoring. Br J Rheumatol. 27:1631988. View Article : Google Scholar : PubMed/NCBI
7	Grahame R, Bird HA and Child A: The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol. 27:1777–1779. 2000.PubMed/NCBI
8	Sutton CW, Rustogi N, Gurkan C, Scally A, Loizidou MA, Hadjisavvas A and Kyriacou K: Quantitative proteomic profiling of matched normal and tumor breast tissues. J Proteome Res. 9:3891–3902. 2010. View Article : Google Scholar : PubMed/NCBI
9	Bijian K, Mlynarek AM, Balys RL, Jie S, Xu Y, Hier MP, Black MJ, Di Falco MR, LaBoissiere S and Alaoui-Jamali MA: Serum proteomic approach for the identification of serum biomarkers contributed by oral squamous cell carcinoma and host tissue microenvironment. J Proteome Res. 8:2173–2185. 2009. View Article : Google Scholar : PubMed/NCBI
10	Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, et al: Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics. 3:1154–1169. 2004. View Article : Google Scholar : PubMed/NCBI
11	Matsumoto K, Satoh K, Maniwa T, Araki A, Maruyama R and Oda T: Noticeable decreased expression of tenascin-X in calcific aortic valves. Connect Tissue Res. 53:460–468. 2012. View Article : Google Scholar : PubMed/NCBI
12	Matsumoto K, Satoh K, Maniwa T, Tanaka T, Okunishi H and Oda T: Proteomic comparison between abdominal and thoracic aortic aneurysms. Int J Mol Med. 33:1035–1047. 2014.PubMed/NCBI
13	Satoh K, Maniwa T, Oda T and Matsumoto K: Proteomic profiling for the identification of serum diagnostic biomarkers for abdominal and thoracic aortic aneurysms. Proteome Sci. 11:272013. View Article : Google Scholar : PubMed/NCBI
14	Beighton P, De Paepe A, Steinmann B, Tsipouras P and Wenstrup RJ: Ehlers-Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers-Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet. 77:31–37. 1998. View Article : Google Scholar : PubMed/NCBI
15	Levy HP: Ehlers-Danlos Syndrome, Hypermobility Type. Gene-Reviews (Internet). Pagon RA, Adam MP, Ardinger HH, et al: Last Update: September 13, 2012. University of Washington; Seattle: 1993–2015
16	Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, Hunter CL, Nuwaysir LM and Schaeffer DA: The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics. 6:1638–1655. 2007. View Article : Google Scholar : PubMed/NCBI
17	Mi H, Muruganujan A and Thomas PD: PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res. 41:D377–D386. 2013. View Article : Google Scholar :
18	Nakamura Y, Takayama N, Minamitani T, Ikuta T, Ariga H and Matsumoto K: Primary structure, genomic organization and expression of the major secretory protein of murine epididymis, ME1. Gene. 251:55–62. 2000. View Article : Google Scholar : PubMed/NCBI
19	Podack ER and Müller-Eberhard HJ: Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem. 254:9808–9814. 1979.PubMed/NCBI
20	Markiewski MM and Lambris JD: The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol. 171:715–727. 2007. View Article : Google Scholar : PubMed/NCBI
21	Mizuno M: A review of current knowledge of the complement system and the therapeutic opportunities in inflammatory arthritis. Curr Med Chem. 13:1707–1717. 2006. View Article : Google Scholar : PubMed/NCBI
22	Breitner S, Störkel S, Reichel W and Loos M: Complement components C1q, C1r/C1s, and C1INH in rheumatoid arthritis. Correlation of in situ hybridization and northern blot results with function and protein concentration in synovium and primary cell cultures. Arthritis Rheum. 38:492–498. 1995. View Article : Google Scholar : PubMed/NCBI
23	Milis L, Morris CA, Sheehan MC, Charlesworth JA and Pussell BA: Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol. 92:114–119. 1993. View Article : Google Scholar : PubMed/NCBI
24	Konttinen YT, Ceponis A, Meri S, Vuorikoski A, Kortekangas P, Sorsa T, Sukura A and Santavirta S: Complement in acute and chronic arthritides: assessment of C3c, C9, and protectin (CD59) in synovial membrane. Ann Rheum Dis. 55:888–894. 1996. View Article : Google Scholar : PubMed/NCBI
25	Blom AM, Villoutreix BO and Dahlbäck B: Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol. 40:1333–1346. 2004. View Article : Google Scholar : PubMed/NCBI
26	Olivar R, Luque A, Naranjo-Gómez M, Quer J, García de Frutos P, Borràs FE, Rodríguez de Córdoba S, Blom AM and Aran JM: The α7β0 isoform of the complement regulator C4b-binding protein induces a semimature, anti-inflammatory state in dendritic cells. J Immunol. 190:2857–2872. 2013. View Article : Google Scholar : PubMed/NCBI
27	Coutaux A, Adam F, Willer JC and Le Bars D: Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine. 72:359–371. 2005. View Article : Google Scholar : PubMed/NCBI
28	Jang JH, Liang D, Kido K, Sun Y, Clark DJ and Brennan TJ: Increased local concentration of complement C5a contributes to incisional pain in mice. J Neuroinflammation. 8:802011. View Article : Google Scholar : PubMed/NCBI
29	Jang JH, Clark JD, Li X, Yorek MS, Usachev YM and Brennan TJ: Nociceptive sensitization by complement C5a and C3a in mouse. Pain. 148:343–352. 2010. View Article : Google Scholar :
30	Thompson A and Danesh J: Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 259:481–492. 2006. View Article : Google Scholar : PubMed/NCBI
31	Sánchez-Enríquez S, Torres-Carrillo NM, Vázquez-Del Mercado M, Salgado-Goytia L, Rangel-Villalobos H and Muñoz-Valle JF: Increase levels of apo-A1 and apo B are associated in knee osteoarthritis: lack of association with VEGF-460 T/C and +405 C/G polymorphisms. Rheumatol Int. 29:63–68. 2008. View Article : Google Scholar : PubMed/NCBI
32	Wilson GN: Exome analysis of connective tissue dysplasia: death and rebirth of clinical genetics? Am J Med Genet A. 164A:1209–1212. 2014. View Article : Google Scholar : PubMed/NCBI